Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04731844 · FLOW

Participant flow

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer · Source last updated 2026-05-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    FG000
    title
    Prostate Cancer
  2. description
    Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    FG001
    title
    Smoldering Multiple Myeloma (SMM)
  3. description
    Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    FG002
    title
    Monoclonal Gammopathy of Unknown Significance (MGUS)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        4
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        12
      2. group Id
        FG001
        num Subjects
        8
      3. group Id
        FG002
        num Subjects
        9
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        9
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        3
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        6
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 30 participants provided informed consent and considered enrolled. Due to withdrawal of consent by one enrolled participant prior to assignment to a treatment arm/group, there are only N=29 assigned to a treatment group after consent. This number (n=29)is reflected in the participant flow.
Complete source fields
groups
  1. description
    Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    FG000
    title
    Prostate Cancer
  2. description
    Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    FG001
    title
    Smoldering Multiple Myeloma (SMM)
  3. description
    Curcumin plus Piperine at a dose of 4 gram/5mg orally BID for 12 months Curcumin plus Piperine: Curcumin with piperine is a well-tolerated over-the-counter supplement.
    id
    FG002
    title
    Monoclonal Gammopathy of Unknown Significance (MGUS)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        2
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        4
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        12
      2. group Id
        FG001
        num Subjects
        8
      3. group Id
        FG002
        num Subjects
        9
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        9
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        3
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        6
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
A total of 30 participants provided informed consent and considered enrolled. Due to withdrawal of consent by one enrolled participant prior to assignment to a treatment arm/group, there are only N=29 assigned to a treatment group after consent. This number (n=29)is reflected in the participant flow.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice